Category B—There are no adequate and well-controlled studies of memantine in pregnant women. NAMENDA should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.
It is not known whether this drug is excreted in human milk.
There were no clinically meaningful differences in most adverse events reported by patient groups ≥65 and <65.
The terminal elimination half-life increased by 18%, 41%, and 95% in subjects with mild, moderate, and severe renal impairment, respectively, compared to healthy subjects. No dosage adjustment is needed in patients with mild or moderate renal impairment. Dosage should be reduced in patients with severe renal impairment.
Administer with caution to patients with severe hepatic impairment.